H.C. Wainwright Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $4
HC Wainwright & Co. Reiterates Buy on Assertio Holdings, Maintains $4 Price Target
Assertio Holdings Analyst Ratings
Promising Buy Rating for Assertio Therapeutics Backed by Positive ROLVEDON Trial Results and Market Potential
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Lake Street Sticks to Its Buy Rating for Assertio Therapeutics (ASRT)
Assertio Holdings Analyst Ratings
H.C. Wainwright Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $4
Assertio Therapeutics: Strong Buy Rating Backed by Robust Margins and Strategic Revenue Growth
Maxim Group Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
A. G. P. Maintains Assertio(ASRT.US) With Buy Rating, Cuts Target Price to $2.15
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Assertio Therapeutics (ASRT) Receives a Buy From Lake Street
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Assertio Therapeutics: Strong Buy Rating on Robust Portfolio and Strategic Growth
Assertio Holdings Price Target Announced at $3.00/Share by Maxim Group
Assertio Holdings Analyst Ratings
Maxim Group Initiates Assertio(ASRT.US) With Buy Rating, Announces Target Price $3